Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

H.R. 3348 · 115th Congress · Jul 20, 2017 · Lineage

A BILL

To expand the tropical disease product priority review voucher program to encourage treatments for the Middle East respiratory syndrome.

This Act may be cited as the “Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act”.

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—

(1)

by redesignating subparagraph (S) as subparagraph (T); and

(2)

by inserting after subparagraph (R) the following:

“(S) Middle East respiratory syndrome.”